Company intelligence / Profile preview

Hubron

Ownership: Private
Development stage: Commercial

Overview

The lead candidate vaccine FMPV3 targets shared tumor-specific neoantigens from frameshift mutations common in several hereditary cancers. It is expected to enter clinical trials in 2025. No published clinical results yet.

Therapeutic areas: Oncology
Modalities: VaccineDiagnostic tool (proprietary technology for frameshift mutation detection)
Industry: Biotech

Partnerships

Extensive network of industrial and academic partners mentioned; specific names not disclosed.

Beyond the preview

Go deeper on Hubron.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hubron.

Explore the full profile